Method for producing heterocyclic methanone compounds and their azabicyclo intermediates

JP2023548368A5Pending Publication Date: 2024-11-07ACTINOGEN MEDICAL LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526903
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

The existing methods for synthesizing zanamem, an inhibitor of 11β-hydroxysteroid dehydrogenase type 1, face challenges such as the need for low temperature reactions using hazardous reagents like n-butyllithium and the formation of genotoxic by-products like tetramethylurea (TMU), making them unsuitable for large-scale production.

Method used

The use of Grignard reaction conditions and amide coupling reactions with specific coupling reagents like carbodiimides avoids the need for low temperatures and eliminates TMU formation, enabling a safe and scalable synthesis of zanamem.

Benefits of technology

This method allows for the efficient and scalable production of high-purity zanamem with reduced undesirable by-products, suitable for both small-scale research and large-scale manufacturing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to methods for synthesizing heterocyclic methanone compounds, particularly 3'-substituted 3-hydroxy-(8-azabicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and azabicyclo intermediates thereof. In particular, the present disclosure also relates to methods for synthesizing Xanamem. The present disclosure also relates to methods for synthesizing optionally protected azabicyclo intermediate compounds. The present invention also relates to 3'-substituted 3-hydroxy-(8-azabicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and azabicyclo intermediates thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This disclosure generally relates to methods for synthesizing heterocyclic methanone compounds, particularly 3'-substituted 3-hydroxy-(8-azabicyclo[3.2.1]octo-8-yl)-[5-(1h-pyrazole-4-yl)-thiophene-3-yl]methanone compounds and their azabicyclo intermediates. In particular, this disclosure also relates to methods for synthesizing zanamem. This disclosure also relates to methods for synthesizing optionally protected azabicyclo intermediate compounds. This disclosure also relates to 3'-substituted 3-hydroxy-(8-azabicyclo[3.2.1]octo-8-yl)-[5-(1h-pyrazole-4-yl)-thiophene-3-yl]methanone compounds and their azabicyclo intermediate compounds prepared by any of the methods of this disclosure. This disclosure also relates to pharmaceutical compositions comprising 3'-substituted, 3-hydroxy-(8-azabicyclo[3.2.1]octo-8-yl)-[5-(1h-pyrazole-4-yl)-thiophene-3-yl]-methanone compounds, particularly zanamem. [Background technology]

[0002] Zanamem, also known as UE2343, is an effective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Due to its inhibitory effect and associated reduction in cortisol levels, zanamem has been proposed as a treatment for Alzheimer's disease. [ka]

[0003] The only reported method for producing zanamem to date is based on International PCT Publication WO2011135276. According to the reported method, zanamem was obtained by synthesizing the carboxylic acid derivative (left) and amine bicyclic derivative (right) of the molecule, respectively, before carrying out the final amide coupling reaction in dichloromethane using the 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) coupling reagent.

[0004] One particular drawback of the reported method identified by the inventors is the synthesis of the right-hand portion of zanamem, especially the coupling of the pyrimidine and nortropinone moieties. This reaction uses n-butyllithium, a highly active autoigniting reagent. Therefore, the reaction must be carefully maintained at extremely low temperatures, particularly -95°C. The addition of n-butyllithium to the reaction mixture causes an exothermic reaction, which increases the temperature of the reaction mixture upon addition. Therefore, this reaction requires the slow addition of n-butyllithium, and the reaction temperature must be carefully monitored throughout the addition of n-butyllithium. While this reaction may be suitable for small-scale synthesis, it is not suitable as a scale-up process for producing large quantities of zanamem.

[0005] Another specific drawback identified by the inventors with respect to the reported method is the final amide coupling reaction between thiophenecarboxylic acid and nortropinoneamine. In this reaction, tetramethylurea (TMU), a by-product utilizing the reaction of the HATU coupling reagent, is itself a potentially genotoxic compound. Furthermore, this TMU by-product is difficult to separate from zanamem during purification. Similarly, this reaction and the associated post-reaction purification steps may be suitable for small-scale synthesis of zanamem, but are not suitable for scale-up processes to produce large quantities of zanamem.

[0006] Therefore, there remains a need for safe, efficient, and scalable synthesis of high-purity zanamem and related analogues, where the generation of undesirable by-products is significantly reduced or avoided. [Overview of the project]

[0007] The subject matter of this disclosure is based on the remarkable discovery that the use of Grignard reaction conditions in the reaction system can avoid the need for low-temperature reaction conditions in the production of azabicyclo intermediate compounds, and / or specific amide coupling reaction conditions for the production of heterocyclic methanone compounds can avoid the genotoxic tetramethylurea (TMU) byproduct, and also result in the efficient and scalable synthesis of zanamem.

[0008] The present invention also relates to a method for producing azabicyclo compounds, comprising a Grignard reaction between a nortropinone compound and a halogenated compound. The present invention also relates to a method for producing heterocyclic methanone compounds, comprising an amide coupling reaction between a heterocyclic carboxylic acid compound and an azabicyclo compound, wherein one or two compounds may be provided in the form of salts as starting materials for the coupling reaction. The disclosure also relates to compounds produced by any of the methods described herein, and any composition comprising these compounds.

[0009] Therefore, in one embodiment, a method for producing a protected azabicyclo compound of formula 4 is provided, comprising a Grignard reaction between a nortropinone compound of formula 5 and a halogenated compound of formula 6. [ka] (In the formula, R 1 The compound is selected from carbocyclyl or heterocyclyl, and each of the carbocyclyl and heterocyclyl compounds is either unsubstituted or contains a halogen, -OH, or -C. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6A monocyclic or bicyclic group substituted with a substituent selected from the group consisting of haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO2R 3 , where R 3 , and R 4 are each independently selected from the group consisting of hydrogen and -C 1~6 alkyl, R 2 is an amine protecting group, X is halogen. )

[0010] In another aspect, there is provided a method for producing a heterocyclic methanone compound of Formula 1, which comprises reacting a carboxylic acid compound of Formula 2 or a salt thereof with an amine compound of Formula 3 or a salt thereof in the presence of at least one coupling reagent selected from an oxime coupling reagent and a carbodiimide coupling reagent.

Chemical formula

[0012] The scope of the present invention is not limited by the specific embodiments described herein, which are for illustrative purposes only. Functionally equivalent products, compositions, and methods as described herein clearly fall within the scope of the present invention.

[0013] Throughout this specification, any reference to individual steps, material compositions, sets of steps, or sets of material compositions shall be deemed to include one or more of these steps, material compositions, sets of steps, or sets of material compositions, unless otherwise specified or required by context. [Brief explanation of the drawing]

[0014] While it will be understood that various embodiments of this disclosure are available, several examples of this disclosure will be described below with reference to the drawings. [Figure 1] Figure 1 shows the HPLC chromatogram of the crude compound A8 reaction mixture at 1.5 hours after the Grignard reaction using i-PrMgBr, Boc-nortropinone, and LaCl3 in THF. [Figure 2] Figure 2 shows the HPLC chromatogram of crude compound A8 after the Grignard reaction of i-PrMgBr, Boc-nortropinone, and LaCl3 in THF. [Figure 3] Figure 3 shows the HPLC chromatogram of purified compound A8 after the Grignard reaction of i-PrMgBr, Boc-nortropinone, and LaCl3 in THF. [Figure 4] Figure 4 shows the HPLC chromatogram of crude compound A8 after a scale-up Grignard reaction using an excess amount of i-PrMgBr (1.7 equivalents). [Figure 5] Figure 5 shows the 1H NMR spectrum of crude compound A8 after a scale-up Grignard reaction using an excess amount of i-PrMgBr (1.7 equivalents). [Figure 6] Figure 6 shows the HPLC chromatogram of crude compound A8 after a scale-up Grignard reaction using the deficient i-PrMgBr (1.3 equivalents). [Figure 7] Figure 7 shows the 1H NMR spectrum of crude compound A8 after a scale-up Grignard reaction using the deficient i-PrMgBr (1.3 equivalents). [Figure 8] Figure 8 shows the HPLC chromatogram of the p-TSA salt of compound A9 after a scale-up (30g to 50g) telescopic reaction. [Figure 9] Figure 9 shows the 1H NMR spectrum of the benzoate of compound A9 after salt screening. [Figure 10] Figure 10 shows the 1H NMR spectrum of the p-TSA salt of compound A9 after salt screening. [Figure 11]Figure 11 shows the 1H NMR spectrum of the mixed component from which compound A9 was extracted, indicating the presence of TsOH. [Figure 12] Figure 12 shows the HPLC chromatogram of purified compound 1 after the amide coupling reaction with compound A9 in p-TSA. [Figure 13] Figure 13 shows the HPLC chromatogram of purified compound 1 after the amide coupling reaction of oximapure and EDC in THF. [Figure 14] Figure 14 shows the HPLC chromatogram of purified compound 1 recrystallized from EtOH / H2O 1:1. [Modes for carrying out the invention]

[0015] General definition Unless otherwise defined, all technical and scientific terms used herein are to be considered to have the same meaning as those commonly understood by those skilled in the art (e.g., chemistry, biochemistry, medicinal chemistry, microbiology, etc.).

[0016] As used herein, the term "and / or," for example "X and / or Y," is understood to mean "X and Y" or "X or Y," and should be understood to clearly support two meanings or either of them, such as A and / or B including any i) A, ii) B, or iii) A and B.

[0017] As used herein, the term “approximately” means + / - 20%, typically + / - 10%, and typically + / - 5% of the specified value, unless otherwise stated. As used herein, the terms “a,” “an,” and “the” include both singular and complex forms unless explicitly indicated otherwise in the context.

[0018] The compounds of this disclosure may contain a chiral center, or the entire molecule may be chiral. Individual stereoisomers (enantiomers and diastereomers) and mixtures thereof are within the scope of the present invention.

[0019] As used herein, the term "halogen" means fluorine, chlorine, bromine, or iodine.

[0020] As used herein, the term “alkyl” includes both linear and branched hydrocarbon groups. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, s-butyl, pentyl, and hexyl. In one example, an alkyl group has 1 to 6 carbon atoms (i.e., C 1~6 It is alkyl.

[0021] As used herein, the term "carbocyclyl" means an aromatic or non-aromatic ring group of carbon atoms. Carbocyclyls may be monocyclic or polycyclic (i.e., dicyclic, tricyclic). Polycyclic carbocyclyls may contain fused rings. In one example, a carbocyclyl has 3 to 10 carbon atoms (i.e., C 3~10 These are carbocyclyls. Examples of monocyclic non-aromatic carbocyclyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Aromatic carbocyclyls include phenyl and naphthalenyl.

[0022] As used herein, the term “heterocyclyl” means an aromatic or non-aromatic ring group similar to a carbocyclyl, but in which one to three carbon atoms are substituted with one or more heteroatoms independently selected from nitrogen, oxygen, or sulfur. Heterocyclyls may be monocyclic or polycyclic (e.g., bicyclic). Polycyclic heterocyclyls may include, for example, fused rings. In bicyclic heterocyclyls, one or more heteroatoms may be present in each ring, or only one heteroatom may be present in one ring. The heteroatoms may be nitrogen, oxygen, or sulfur. Heterocyclyls containing a suitable nitrogen atom contain the corresponding N-oxide. In one example, a heterocyclyl has 3 to 10 atoms (i.e., a 3 to 10-membered heterocyclyl). Examples of monocyclic non-aromatic heterocyclines include azilidinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, tetrahydrofuranil, tetrahydropyranil, morpholinil, thiomorpholinil, and azepanil. Examples of bicyclic heterocyclines in which one ring is non-aromatic include dihydrobenzofuranil, indanyl, indlinyl, isoindlinyl, tetrahydroisoquinolinil, tetrahydroquinolyl, and benzoazepanil. Examples of monocyclic aromatic heterocyclines (also called monocyclic heteroaryls) include furanil, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, isothiazolyl, isoxazolyl, pyrazinyl, pyrazolyl, and pyrimidine. Examples of bicyclic aromatic heterocyclyls (also called bicyclic heteroaryls) include quinoxalinyl, quinazolinyl, pyridopyradinyl, benzoxazolyl, benzothiophenyl, benzimidazolyl, naphthilidinyl, quinolinyl, benzofuranil, indolyl, benzothiazolyl, oxazolyl[4,5-b]pyridyl, pyridopyrimidinyl, isoquinolinyl, and benzohydroxazole.

[0023] As used herein, the term “anion” refers to an ion with a negative charge. Similarly, as used herein, the term “cation” refers to an ion with a positive charge.

[0024] This disclosure relates to compounds of formula 1 and salts thereof. In embodiments of the compounds of formula 1, salts containing a suitable acidic or basic group can be formed. Preferred salts of the compounds of formula 1 include salts formed with organic or inorganic acids or bases. As used herein, the term "pharmaceutically acceptable salt" means a pharmaceutically acceptable organic or inorganic salt. Exemplary acid addition salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, bisulfates, phosphates, acidic phosphates, isonicotinates, lactates, salicylates, acidic citrates, tartrates, oleates, tannates, pantothenates, bistartrates, ascorbicates, succinates, maleates, gentisinates, fumarates, glucons, glucurons, sugarates, formates, benzoates, glutamates, methanesulfons, ethanesulfons, benzenesulfons, p-toluenesulfons, and pamoates (i.e., 1,1'-methylenebis-(2-hydroxy-3-naphthoic acid)) salts. Examples of base addition salts include, but are not limited to, ammonium salts, alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and salts with organic bases such as dicyclohexylamine, N-methyl-D-glucomine, morpholine, thiomorpholine, piperidine, pyrrolidine, mono-, di- or tri-lower alkylamines such as ethyl-, t-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or mono-, di- or tri-lower alkylamines, trihydroxy lower alkylamines such as mono-, di- or triethanolamine. A pharmaceutically acceptable salt may contain other molecules such as acetate ions, succinate ions, or other counterions. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have one or more charged atoms in its structure. If multiple charged atoms are part of a pharmaceutically acceptable salt, it may have multiple counterions.Therefore, pharmaceutically acceptable salts may have one or more charged atoms and / or one or more counterions. Furthermore, non-pharmaceutically acceptable salts may be used as intermediates for the production of pharmaceutically acceptable salts, or for storage or transport, and should therefore be understood to be included within the scope of this disclosure.

[0025] Those skilled in the art of organic and / or medicinal chemistry will understand that many organic compounds can form complexes with solvents and react, precipitate, or crystallize in the solvent. These complexes are known as “solvates.” For example, a complex with water is known as a “hydrate.” As used herein, the terms “pharmaceutically acceptable solvate” or “solvate” mean the association of one or more solvent molecules with the compounds of the present disclosure. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. It should be understood that the present disclosure includes solvated forms, including the compounds of Formula 1 and hydrates of their salts.

[0026] Those skilled in the art of organic and / or medicinal chemistry will understand that the compounds of formula 1 and their salts may exist in amorphous or crystalline forms. It should be understood that this disclosure includes all forms and polymorphs of the compounds of formula 1 and their salts.

[0027] For clarity, it should be understood that some features described herein in the context of individual embodiments may also be provided in combination in a single embodiment. In contrast, various features described in the context of a single embodiment may, for the sake of brevity, be provided individually or in any subcombination.

[0028] Throughout this specification, various aspects and components of the invention may be expressed in range form. Range form is included for convenience and should not be construed as an inflexible limitation on the scope of the invention. Therefore, unless otherwise noted, range descriptions should be considered to specifically disclose all possible subranges and the individual numerical values ​​within those ranges. For example, a range description such as 1–5 should be considered to have specifically disclosed subranges such as 1–3, 1–4, 1–5, 2–4, 2–5, 3–5, etc. Unless an integer is required or implied by the context, individual and partial digits within the enumerated range are included, such as 1, 2, 3, 4, 5, 5.5, 6. This applies regardless of the breadth of the disclosed range. If a specific value is required, this will be stated in the specification.

[0029] Throughout this specification, variations of the phrase "comprise," "comprises," or "comprising" shall be understood to indicate that the specified element, integer, or step, or group of elements, integers, or steps, is included, but not to indicate that other elements, integers, or steps, or other groups of elements, integers, or steps are excluded.

[0030] Despite the numerous prior art publications cited herein, it should be clearly understood that these citations do not constitute an admission that any of these documents constitute part of the publicly known art in Australia or any other country.

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. In carrying out or testing the present invention, similar or equivalent methods and materials may be used, but suitable methods and materials are listed below. In case of any conflict, this specification (including definitions) shall prevail. Furthermore, the materials, methods, and examples are illustrative and not limiting. Zanamem manufacturing method

[0032] The subject matter of this disclosure is based on a remarkable discovery regarding an efficient and scalable method for producing zanamem. The following Scheme 1 provides a non-limiting example of an effective and scalable method for producing zanamem and related compounds (compounds of Formula 1). [ka]

[0033] The above process will be further described below in relation to each step. Each step may provide its own independent method, embodiment, or example for producing the intermediate or the compound itself, or it may provide another embodiment or example of another method or embodiment described herein. Each intermediate or compound produced in each step may also provide its own independent method, embodiment, or example related to those compounds, compositions and / or methods.

[0034] Synthesis of compound A3 In some embodiments, compound A3 is produced by the reaction of compound A1 and compound A2. [ka]

[0035] As used herein, the term “LG” means “leaving group” and can be any molecular fragment that leaves with a pair of electrons in heterolytic bond cleavage. In some embodiments, the leaving group (LG) is an anion. In some embodiments, the leaving group (LG) is a cation. In some embodiments, the leaving group (LG) is a neutral molecular fragment. Examples of anionic leaving groups (LG) include, but are not limited to, halides. In some embodiments, the leaving group (LG) is a halide. In some embodiments, the leaving group (LG) is a halide and chlorine (Cl -), bromine (Br - ) and iodine (I - Selected from the group consisting of ). For example, LG is chlorine (Cl - ) is. For example, LG is bromine (Br - ) is. For example, LG is iodine (I - In some embodiments, LG is a boronic acid ester derivative. The introduction of a boronic acid ester derivative can be achieved by the Miyaura borylation reaction. In one example, LG is a boronic acid ester derivative having the following structure. [ka]

[0036] R 5 R may be a hydrogen or amine protecting group. In some embodiments, 5 is hydrogen. In some embodiments, R 5 R is an amine protecting group. As used herein, the term “protecting group” means a molecular fragment that chemically modifies a functional group to obtain chemoselectivity in a subsequent chemical reaction. Specifically, the term “amine protecting group” refers to a protecting group that chemically modifies an amine functional group to obtain chemoselectivity in a subsequent chemical reaction. Examples of amine protecting groups include, but are not limited to, urethane, amide, benzyl, benzylidene, tosyl, and trityl protecting groups. In some embodiments, R 5 R is an amino protecting group selected from the group consisting of urethane, amide, benzyl, benzylidene, tosyl, and trityl protecting groups. Examples of urethane protecting groups include, but are not limited to, methyl and ethyl, 9-fluoroenylmethyl, 9-fluoroenylmethyloxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), benzylcarbamate (Cbz), and p-methoxybenzylcarbonyl (MeOZ). In some embodiments, R 5is a t-butoxycarbonyl (Boc) protecting group. Examples of amide protecting groups include, but are not limited to, acetyl (Ac), benzamide, trifluoroacetamide, trichloroacetamide, phenylacetamide, picolinamide, and phthalimide. Other examples of amino protecting groups include, but are not limited to, benzoyl, benzyl, benzylidene, p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts), trichloroethyl chloroformate (Troc), toluenesulfonyl, trityl, and triphenylmethyl.

[0037] In some embodiments, R 5 This is the tetrahydropyran (THP) portion, as shown below. [ka]

[0038] In some embodiments, compound A1 is as follows: [ka]

[0039] X may be a functional group capable of reacting with the leaving group (LG) of compound A1 to form a carbon-carbon single bond. In some embodiments, X is a halide. In some embodiments, X is selected from the group consisting of chlorine, bromine, and iodine. In one example, X is chlorine. In one example, X is bromine. In one example, X is iodine.

[0040] R 6 R may be a hydrogen protecting group or an ester protecting group. In some embodiments, 6 is hydrogen. In some embodiments, R 6R is an ester protecting group. As used herein, the term “ester protecting group” means a molecular fragment that chemically modifies an ester functional group to obtain chemoselectivity in a subsequent chemical reaction. In some embodiments, R 6 R is a linear or branched alkyl chain. In some embodiments, R 6 C is a linear or branched chain. 1~6 It is an alkyl chain. In some embodiments, R 6 C 1~6 It is an alkylaryl. In some embodiments, R 6 The group is selected from methyl (CH3), ethyl (CH2CH3), propyl (CH2CH2CH3), benzyl, and t-butyl (C(CH3)3). In one example, R 6 It is methyl. For example, R 6 It is ethyl. For example, R 6 It is benzyl.

[0041] In some embodiments, compound A2 is as follows: [ka]

[0042] Under appropriate conditions as understood by those skilled in the art, compound A1 and compound A2 are reacted to form compound A3. In some embodiments, compound A3 is obtained by reacting compound A1 and compound A2 under Suzuki reaction conditions. Suzuki reaction conditions are also called Suzuki-Miyaura reaction conditions or Suzuki coupling conditions. As understood by those skilled in the art, the Suzuki reaction is a cross-coupling reaction in which the coupling partners are a boric acid / ester derivative and an organic halide, and this reaction is catalyzed by a metal catalyst in the presence of a base.

[0043] The metal catalyst is usually a palladium catalyst, but a nickel catalyst may also be used. In some embodiments, the reaction is catalyzed by a palladium catalyst. In some embodiments, the reaction is catalyzed by a nickel catalyst. In some embodiments, the reaction is catalyzed by a catalyst selected from the group consisting of Pd(Amphos)2Cl2, Pd(PPh3)4, Pd2(dba)3, Pd(OAc)2, PdCl2(dppf), Ni(cod)2, NiCl2-glyme, NiCl2(PCy3)2, NiCl2(dppp), and NiCl2(PPh3)2. In one example, the metal catalyst is Pd(amphos)2Cl2. In some embodiments, with respect to compound A2, about 0.01 to 0.1 equivalents, about 0.01 to 0.05 equivalents, or about 0.02 to 0.025 equivalents of the metal catalyst are used in the reaction.

[0044] This reaction may be further catalyzed by phosphine ligand derivatives. Examples of such ligands include, but are not limited to, BrettPhos, AdBrettPhos, tBuBrettPhos, RuPhos, CPhos, AlPhos, SPhos, XPhos, MePhos, JohnPhos, CyJohnPhos, XantPhos, and DavePhos.

[0045] The base is generally a water-soluble base. In some embodiments, the base is selected from the group consisting of potassium carbonate (K2CO3), potassium t-butoxide (KOtBu), cesium carbonate (Cs2CO3), tripotassium phosphate (K3PO4), sodium hydroxide (NaOH), and triethylamine (NEt3). In one example, the base is potassium carbonate (K2CO3). In some embodiments, about 1 to 5 equivalents, about 1 to 2 equivalents, or about 1 to 1.5 equivalents of the base are used in the reaction with respect to compound A2.

[0046] As will be understood by those skilled in the art, the reaction can be carried out in a variety of suitable solvent systems. In some embodiments, the solvent is an aqueous solvent, such as a mixture containing water. In some embodiments, the solvent is a two-phase mixture containing water. In some embodiments, the solvent is a two-phase mixture containing water and one or more ether solvents. The aqueous solvent or two-phase mixture may contain or consist of a solvent selected from the group consisting of water, polar ether solvents, nonpolar ether solvents, or combinations thereof. Using a two-phase mixture offers unexpected additional advantages, such as further reduction of trace impurities, such as catalysts like palladium.

[0047] In some embodiments, the reaction is carried out in a polar solvent, such as a polar protic solvent, a polar aprotic solvent, or a combination thereof. In some embodiments, the reaction is carried out in a nonpolar solvent, such as a nonpolar aprotic solvent. Examples of polar protic solvents include, but are not limited to, water, alcohols, and glycols. Examples of alcohols include, but are not limited to, methanol (MeOH), ethanol (EtOH), 1-propanol, isopropanol (2-propanol, iPrOH, or IPA), 1-butanol, 2-butanol, t-butanol (t-BuOH), 1-pentanol, 3-methyl-1-butanol, and 2-methyl-1-propanol. Examples of glycols include, but are not limited to, ethylene glycol. Examples of polar aprotic solvents include, but are not limited to, halogenated hydrocarbons, ketones, nitriles, esters, carbonate esters, ethers, sulfoxides, sulfones, amides, nitroalkanes, and pyrrolidines. Examples of ketones include, but are not limited to, acetone, methyl ethyl ketone (MEK), methyl butyl ketone (MBK), methyl isobutyl ketone (MIBK), and methyl isopropyl ketone. Examples of nitriles include, but are not limited to, acetonitrile (MeCN). Examples of esters include, but are not limited to, ethyl formate, methyl acetate (MeOAc), ethyl acetate (Â), propyl acetate, isopropyl acetate (iPAC), n-butyl acetate, and isobutyl acetate. Examples of carbonate esters include, but are not limited to, dimethyl carbonate (DMC) and propylene carbonate (PC).Examples of polar and nonpolar ethers include, but are not limited to, methyl-t-butyl ether (MTBE), diethyl ether, 1,4-dioxane, 2-methoxyethanol, 2-ethoxyethanol, dimethoxyethane (DME or monoglyme), 1,1-dimethoxymethane, 2,2-dimethoxypropane, 1,1-diethoxypropane, isopropyl ether, petroleum ether, cyclopentyl methyl ether (CPME), anisole (methoxybenzene), methyltetrahydrofuran (MeTHF), and tetrahydrofuran (THF). Examples of sulfoxides include, but are not limited to, dimethyl sulfoxide (DMSO). Examples of sulfones include, but are not limited to, sulfolane. Examples of amides include, but are not limited to, carboxamide, N,N-dimethylacetamide, and N,N-dimethylcarboxamide (DMF). Examples of nitroalkanes include, but are not limited to, nitromethane. Examples of pyrrolidines include, but are not limited to, N-methylpyrrolidone (NMP). Examples of polar and nonpolar halogenated hydrocarbons, such as chlorinated hydrocarbons, include, but are not limited to, dichloromethane (DCM), chloroform, 1,2-dichloroethane, 1,1,1-trichloroethane, 1,1-dichloroethylene, and 1,2-dichloroethylene. In one example, the reaction is carried out in an ether such as CPME and MeTHF.

[0048] In some embodiments, the solvent comprises or consists of water and one or more polar aprotic ether solvents such as CPME and MeTHF.

[0049] In one example, the reaction conditions use Pd(Amphos)2Cl2 as a catalyst, potassium carbonate (K2CO3) as a base, and diethyl ether / water as a solvent. According to any example described herein, the ether may be a polar ether such as CPME and / or MeTHF.

[0050] This reaction forms compound A3, and here, R 5 and R 6 This is as described herein. For example, compound A3 is as follows: [ka]

[0051] In the synthesis of zanamem and its analogues, compound A3 may be used in the sequential synthesis steps either without purification (i.e., obtained as a crude reaction product and reacted with) or after being initially separated and / or purified. Those skilled in the art will understand appropriate separation and / or purification techniques.

[0052] Synthesis of compound A4 In some embodiments, compound A4 is derived from compound A3 to R 5 It is manufactured by deprotecting it. [ka]

[0053] R 5 and R 6 This is as described herein. As will be understood by those skilled in the art, when compound A3 is reacted under appropriate reaction conditions, compound A4 is formed. 5 Deprotection yields the free secondary amine (-N(H)-) of compound A4. In some embodiments, R 5 The following applies: [ka]

[0054] Also, R 5Acidic reaction conditions are necessary to deprotect the amine to which the compound is bonded. In one example, the acidic reaction conditions include hydrochloric acid (HCl). An excess amount of hydrochloric acid may be required. In some embodiments, at least about 1.5, 2, 3, 4, or 5 equivalents of hydrochloric acid (HCl) are used in the reaction with compound A3. In one example, about 4 equivalents of hydrochloric acid (HCl) are used in the reaction with compound A3.

[0055] Those skilled in the art will understand that several suitable solvents can be used in the reaction. Any one or more of the aforementioned solvents described above for the production of compound A3 can be used in the reaction for the production of compound A4. In one example, the solvent is a two-phase solvent according to any of the examples described herein. In one example, the solvent includes esters and / or ethers. In another example, the solvent includes ethers such as cyclopentyl methyl ether (CPME) and 2-methyltrihydrofuran (2-MeTHF). Those skilled in the art will understand that heating may be necessary to accelerate the reaction. In some embodiments, the reaction is heated to about 30°C to 80°C, about 40°C to 70°C, or about 45°C to 55°C. In one example, the reaction is heated to about 50°C.

[0056] Purification can be carried out by recrystallization, which in some examples can be achieved using a solvent selected from ester and / or ether solvents.

[0057] Synthesis of compound A5 In some embodiments, compound A5 is derived from compound A4. 6 It is produced by hydrolysis. [ka]

[0058] R 6 This is as described herein. As will be understood by those skilled in the art, compound A4 is reacted under appropriate reaction conditions to produce R 6Compound A5 is obtained by hydrolysis of . In some embodiments, this reaction is an ester hydrolysis reaction. 6 Hydrolysis of the group yields a carboxylic acid group on compound A5.

[0059] The hydrolysis reaction may be acid-catalyzed or base-catalyzed. In some embodiments, the hydrolysis reaction is acid-catalyzed. In some embodiments, the hydrolysis reaction is base-catalyzed. Examples of preferred acids include, but are not limited to, hydrochloric acid (HCl). Examples of preferred bases include, but are not limited to, sodium hydroxide (NaOH), potassium hydroxide (KOH), and lithium hydroxide (LiOH). In some embodiments, the hydrolysis reaction is catalyzed by a lithium hydroxide (LiOH) base. In one example, the base is in the form of lithium hydroxide monohydrate (LiOH,H2O).

[0060] Those skilled in the art will understand that several suitable solvents can be used in the reaction. Any one or more of the aforementioned solvents described above for the production of compound A3 or compound A4 can be used in the reaction for the production of compound A5. In one example, the solvent is a two-phase solvent according to any example described herein. In one example, the solvent includes esters and / or ethers. In another example, the solvent includes ethers such as cyclopentyl methyl ether (CPME) and 2-methyltrihydrofuran (2-MeTHF).

[0061] Those skilled in the art will understand that heating may be necessary to accelerate the reaction. In some embodiments, the reaction is heated to about 30°C to 70°C, about 30°C to 50°C, or about 30°C to 40°C. In one example, the reaction is heated to about 35°C.

[0062] Synthesis of compound A8 In some embodiments, compound A8 is produced by the reaction of compound A6 and compound A7. [ka]

[0063] In some embodiments, a method for producing the protected amine compound A8 of formula 4 is provided. [ka]

[0064] This manufacturing method involves the nortropinone compound A7 of formula 5 and [ka] TIFF2023548368000019.tif9159

[0065] This includes a Grignard reaction with halogenated compound A6 of formula 6. [ka]

[0066] In some embodiments, R 1 It is a carbocyclyl or heterocyclyl. For example, R 1 It is carbocyclyl. In one example, R 1 is a heterocyclyl. In some embodiments, each of the carbocyclyl or heterocyclyl is a monocyclic or bicyclic group. In one example, the carbocyclyl is a monocyclic group. In another example, the carbocyclyl is a bicyclic group. In another example, the heterocyclyl is a monocyclic group. In yet another example, the heterocyclyl is a bicyclic group. In some embodiments, each of the carbocyclyl and heterocyclyl is unsubstituted or contains a halogen, -OH, -C, respectively. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO2R 3A monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of. In some embodiments, each of the carbocyclic and heterocyclic groups is an unsubstituted monocyclic or bicyclic group, respectively. In some embodiments, each of the carbocyclic and heterocyclic groups is halogen, -OH, -C 1~6 alkyl, -O-C 1~6 alkyl, -C 1~6 haloalkyl, -O-C 1~6 haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO2R 3 A monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of.

[0067] In some embodiments, R 1 is each unsubstituted or a monocyclic or bicyclic heteroaryl substituted with one or more substituents selected from the group consisting of halogen, -OH, -C 1~6 alkyl, -O-C 1~6 alkyl, C 1~6 haloalkyl, -O-C 1~6 haloalkyl. In some embodiments, R<​​​​​​​​​​​​​​​​​​R is an amine protecting group selected from the group consisting of urethanes (e.g., t-butyloxycarbonyl (BOC), t-butylcarbamate BOC, 9-fluorenylmethylcarbamate FMOC, benzylcarbamate CBZ), amides (e.g., acetamide Ac, trifluoroacetamide, phthalimide), benzyl, benzylidene, tosyl (e.g., toluenesulfonyl), and trityl (e.g., triphenylmethyl). In one example, R 2 It is t-butoxycarbonyl (BOC).

[0069] In some embodiments, R 3 and R 4 These are, independently, hydrogen and C 1~6 Selected from the group consisting of alkyl groups. For example, R 3 is hydrogen. In one example, R 3 C 1~6 It is alkyl. For example, R 4 is hydrogen. In one example, R 4 C 1~6 It is alkyl.

[0070] In some embodiments, X is a halogen. In some embodiments, X is selected from the group consisting of chlorine, bromine, and iodine. In some embodiments, X is chlorine. In some embodiments, X is bromine. In some embodiments, X is iodine.

[0071] In some embodiments, the Grignard reaction comprises: i) a halogen-metal exchange reaction step including a Grignard reagent, and ii) a coupling reaction step including LaCl3.

[0072] In some embodiments, the Grignard reagent is selected from the group consisting of i-PrMgBr, i-PrMgCl.LiCl ("Turbo Grignard" reagent), and sec-BuMgCl.LiCl. In one example, the Grignard reagent is i-PrMgBr.

[0073] In some embodiments, the halogen-metal exchange reaction advantageously avoids the need for cryogenic cooling conditions. In some embodiments, the halogen-metal exchange reaction involving i-PrMgBr is carried out between approximately -40°C and approximately 20°C, approximately -30°C and approximately 10°C, or approximately -20°C and approximately 0°C. In one example, the halogen-metal exchange reaction involving i-PrMgBr is carried out between approximately -20°C and 0°C. In another example, the halogen-metal exchange reaction involving i-PrMgBr is carried out between approximately -20°C and -15°C. In some embodiments, i-PrMgBr is added to the reaction mixture between approximately -20°C and -15°C.

[0074] In some embodiments, the halogen-metal exchange reaction involving i-PrMgBr is carried out using about 1 to 3 equivalents of i-PrMgBr, about 1 to 2 equivalents of i-PrMgBr, or about 1.1 to 1.5 equivalents of i-PrMgBr. In some embodiments, the halogen-metal exchange reaction involving i-PrMgBr is carried out using at least about 1, 1.1, 1.2, 1.3, 1.4, or 1.5 equivalents of i-PrMgBr. In some embodiments, the halogen-metal exchange reaction involving i-PrMgBr is carried out using equivalents of i-PrMgBr for less than about 3, 2.5, 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, or 1.2 times. In some embodiments, the halogen-metal exchange reaction involving i-PrMgBr is carried out using equivalents of i-PrMgBr in an amount between any two of the above upper and / or lower limits.

[0075] In some embodiments, after the i-PrMgBr has been completely added, the reaction mixture is stirred for t minutes before being heated to about 0°C. In some embodiments, t is between about 5 minutes and about 60 minutes, about 10 minutes and about 45 minutes, or about 20 minutes and about 40 minutes. In some embodiments, t is about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 45 minutes, or about 60 minutes. In one example, t is about 30 minutes. That is, in one example, the duration of the halogen-metal exchange reaction is about 30 minutes.

[0076] After raising the reaction mixture to approximately 0°C, a coupling reaction involving LaCl3 is carried out. In some embodiments, the coupling reaction occurs at approximately 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C. In some embodiments, the coupling reaction occurs between approximately 0°C and 20°C, 0°C and 10°C, or between approximately 0°C and 5°C. In one example, the coupling reaction occurs between approximately 0°C and 5°C.

[0077] In some embodiments, the amount of LaCl3 used in the reaction is between approximately 1–3 equivalents, approximately 1.1–2 equivalents, approximately 1.2–1.8 equivalents, or approximately 1.4–1.6 equivalents. In one example, the amount of LaCl3 used in the reaction is approximately 1.5 equivalents.

[0078] For example, LaCl3 is LaCl3.2LiCl.

[0079] Those skilled in the art will understand that several suitable solvents can be used in the reaction. Any one or more of the aforementioned solvents for compounds A3, A4, or A5 can be used in the reaction to produce compound A8. In one example, the solvent includes esters and / or ethers. In another example, the solvent includes ethers such as cyclopentyl methyl ether (CPME) and 2-methyltrihydrofuran (2-MeTHF). The solvent can be present in the reaction in any suitable amount to bring the reaction to fruition. In some examples, the solvent may be anhydrous. For example, the amount of water in the solvent may be about 500, 400, 300, 200, 100, 75, 50, 25, 10, 5, or less than 1 ppm.

[0080] In some embodiments, the reaction may be monitored to quench the Grignard reaction when a certain amount of Grignard reagent is added, for example, so that the conversion rate is at least 50%, 75%, 90%, or 95%, before the compound A8 is completely converted. The reaction mixture may be quenched by pouring it into an acid, such as an aqueous solution containing citric acid.

[0081] In some embodiments, compound A8 of formula 4 is the compound of formula 4a. [ka]

[0082] The method involves reacting compound A7 of formula 5a with compound A6 of formula 6a. [ka]

[0083] In the synthesis of zanamem and its analogues, compound A8 of formula 4 may or may not be purified before proceeding to the next synthesis step or reaction. In one example, compound A8 of formula 4 is purified. Conventional column chromatography is suitable for separating compound A8 of formula 4 with good purity. In one example, compound A8 is purified by column chromatography. In another example, compound A8 is not purified before proceeding to the subsequent synthesis reaction. That is, in the synthesis of compound A9 of formula 3, the crude raw material is reacted directly. Such carry-through of the crude raw material is called "telescopeing" the crude raw material into the subsequent chemical reaction in this field.

[0084] Synthesis of compound A9 In some embodiments, compound A9 is derived from compound A8 to R 2 It is produced by deprotecting and, in some cases, forming a salt of compound A9. The salt can be formed as a monosalt or a double salt, for example, as follows: [ka]

[0085] As described herein, R 1 and R 2 This may be provided according to any embodiment or example.

[0086] In some embodiments, a method for producing the azabicyclo compound A9 of formula 3 or a salt thereof is provided. [ka]

[0087] This manufacturing method involves removing the amine protecting group from compound A8 of formula 4 and chlorinating it as necessary.

[0088] Compound A8 can be used as the crude product from the previous reaction, as described, and can be directly used as a starting material in the preparation of compound A9 of formula 3, for example.

[0089] It should be understood that amine protecting groups can be removed by any suitable method known to those skilled in the art, depending on the nature of the protecting group. In some embodiments, amine protecting groups are removed under acidic conditions, such as with acids including hydrochloric acid, acetic acid, or sulfonic acid. In one example, the protecting group is a BOC protecting group and is removed under acidic conditions. In another example, the protecting group is a BOC protecting group and is removed under aqueous hydrochloric acid (HCl) conditions. In yet another example, the protecting group is a BOC protecting group and is removed under trifluoroacetic acid (TFA) conditions. In yet another example, the acidic conditions include sulfonic acid. The sulfonic acid may be a substituted alkyl or aromatic sulfonic acid, such as p-toluenesulfonic acid (also called toluenesulfonic acid TsOH). In one example, the protecting group is a BOC protecting group and is removed under sulfonic acid conditions such as toluenesulfonic acid (TsOH). The use of sulfonic acid can offer further advantages, such as the rapid precipitation of the reaction product to form single or bitoluenesulfonates.

[0090] Compound A9 of Formula 3 may be salted out as needed. As used herein, the term “chlorination” means converting a chemical substance into the form of its salt. In some embodiments, compound A9 of Formula 3 reacts in the form of its salt in subsequent chemical reactions. By converting compound A9 of Formula 3 to its salt, more stable (e.g., less decomposing) intermediates can be produced. Those skilled in the art will understand that many suitable salts can be used. In one example, a chloride is produced using a sulfonic acid such as p-toluenesulfonic acid (p-TSA or TsOH) to form a toluenesulfonate of compound A9 of Formula 3. Sulfonic acids have been found to effectively provide both the function of deprotecting the amine protecting group and chlorinating the resulting deprotected compound. Chlorination can provide monosal or double salts, such as bistoluenesulfonates (e.g., pTSA:nortropinone in the range of 1:1 to 2:1). The formation of salts, especially when prepared as double salts, has been found to offer further advantages in purification by rapid crystallization and precipitation from solution, providing stable salt compounds that can be used directly (e.g., without further purification) in subsequent amide coupling reactions.

[0091] Those skilled in the art will understand that several suitable solvents can be used in the reaction. One or more of the solvents of compounds A3, A4, A5, and A8 can be used in the reaction to produce compound A9. In one example, the solvent is selected from the group consisting of water, alcohols, esters, ethers, or combinations thereof. The solvent may be an aqueous solvent. The solvent may contain an acid as in any of the above examples. In one example, the solvent contains ethers such as cyclopentyl methyl ether (CPME) and 2-methyltrihydrofuran (2-MeTHF). In another example, the solvent contains an alcohol, such as isopropyl alcohol (IPA). The solvent can be present in the reaction in any suitable amount to accomplish the reaction. The amount of acid present in the reaction (in moles / liter) is about 0.1–2, 0.2–1, or 0.3–0.7. The acid may be present during the reaction in amounts of at least 1, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5 in molar equivalents of compound A9 of formula 3, and / or less than about 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, 2.0, or 1.5, or in the range provided by any two of these upper and / or lower limits, for example, between 2 and 5 or between 2.5 and 4.5.

[0092] Synthesis of Compound 1 In some embodiments, the heterocyclic methanone compound 1 is produced by an amide coupling reaction between a carboxylic acid compound A5 or a salt thereof and an azabicyclo compound A9 or a salt thereof.

[0093] In some embodiments, a method for producing the heterocyclic metanon compound 1 of formula 1 is provided. [ka] (In the formula, R 1 (This refers to any embodiment or example thereof as defined herein.)

[0094] This manufacturing method involves reacting a carboxylic acid compound of formula 2 or a salt thereof with an azabicyclo compound of formula 3 or a salt thereof prepared herein. [ka]

[0095] In some embodiments, the carboxylic acid compound A5 is provided in the form of a salt, such as a halide salt (e.g., a chloride).

[0096] In some embodiments, the azabicyclo compound A9 is provided in the form of a salt, such as a monosalt, a double salt, or a combination thereof. [ka]

[0097] In some examples, the monosal or double salt of azabicyclo compound A9 is a sulfonate, such as toluenesulfonate, as described in any of the examples herein.

[0098] In some examples, compound A9 of formula 3 is the double sulfonate of formula 3a. [ka] (In the formula, R is selected from alkyl, aryl, and alkylaryl, which may be optionally substituted.)

[0099] Examples of sulfonates include mesylate (methanesulfonate), triflate (trifluoromethanesulfonate), ethanesulfonate (esylate), toluenesulfonate (p-toluenesulfonate), benzenesulfonate (besylate), crosylate (crosylate, chlorobenzenesulfonate), camphorsulfonate (cansylate), pipesylate (p-iodobenzenesulfonate), or nosylate. One example of a sulfonate is toluenesulfonate.

[0100] In some embodiments, an equimolar or excess molar equivalent of carboxylic acid compound A9 or a salt thereof is used relative to azabicyclo compound A5 or a salt thereof. For example, the molar equivalent of carboxylic acid compound A9 or a salt thereof relative to azabicyclo compound A5 or a salt thereof is at least 1, 1.05, 1.1, 1.15, 1.2, 1.25, 1.3, 1.35, 1.4, 1.45, or 1.5.

[0101] In some embodiments, a method for producing a heterocyclic methanone compound of formula 1 is provided. [ka] TIFF2023548368000030.tif9163

[0102] This manufacturing method involves reacting a carboxylic acid compound of formula 2 or a salt thereof with an amine compound of formula 3 or a salt thereof in the presence of at least one coupling reagent selected from the group consisting of oxime coupling reagents and carbodiimide coupling reagents. [ka]

[0103] R in the formula 1 The compound may be selected from carbocyclyl or heterocyclyl, each of which is either unsubstituted or contains a halogen, -OH, or -C. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO2R 3 A monocyclic or bicyclic group substituted with one or more substituents, R 3 , and R 4 These are, independently, hydrogen and C 1~6 Selected from the group consisting of alkyl groups. 5This may be a hydrogen or amine protecting group, according to any embodiment or example described herein.

[0104] In some embodiments, R 1 is a carbocyclyl or a heterocyclyl. In some embodiments, each of the carbocyclyl or heterocyclyl is a monocyclic or bicyclic group. In one example, the carbocyclyl is a monocyclic group. In another example, the carbocyclyl is a bicyclic group. In another example, the heterocyclyl is a monocyclic group. In yet another example, the heterocyclyl is a bicyclic group. In some embodiments, each of the carbocyclyl and heterocyclyl is either unsubstituted or contains a halogen, -OH, or -C. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO2R 3 A monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of the following. In some embodiments, each of the carbocyclyl and heterocyclyl is an unsubstituted monocyclic or bicyclic group. In some embodiments, each of the carbocyclyl and heterocyclyl is a halogen, -OH, -C, respectively. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO2R 3 A monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of the following.

[0105] In some embodiments, R 1 These are either unsubstituted, halogen, -OH, or -C, respectively. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6It is a monocyclic or bicyclic heteroaryl substituted with one or more substituents selected from the group consisting of haloalkyls. In some embodiments, R 1 These are either unsubstituted, halogen, -OH, or -C. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6 A pyrimidine substituted with one or more substituents selected from the group consisting of haloalkyls. In some embodiments, R 1 It is an unsubstituted pyrimidine.

[0106] As used herein, the term “coupling reagent” means a compound capable of forming a chemical bond between two chemical moieties. For example, a coupling reagent is an “amide coupling reagent,” which forms an amide bond by establishing a chemical bond between a carboxylic acid moiety and an amine moiety. The coupling reagent may be accompanied by the use of one or more additives or one or more base compounds to facilitate the coupling reaction.

[0107] In some embodiments, the amide coupling reagent is at least one coupling reagent selected from the group consisting of carbodiimide coupling reagents and oxime coupling reagents. In some embodiments, the amide coupling reagent is a carbodiimide coupling reagent. In some embodiments, the carbodiimide coupling reagent is selected from the group consisting of DCC (dicyclohexylcarbodiimide), DIC (diisopropylcarbodiimide), EDAC.HCl (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide·HCl), EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), and combinations thereof. In one example, the carbodiimide coupling reagent is EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). In another example, the carbodiimide coupling reagent is DIC (diisopropylcarbodiimide).

[0108] In some embodiments, the coupling reagent is an oxime coupling reagent. In some embodiments, the oxime coupling reagent is selected from the group consisting of Oxyma Pure (2-cyano-2-(hydroxyimino)acetate), K-Oxyma (2-cyano-2-(hydroxyimino)acetic acid) potassium, COMU (1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethyl-aminomorph-orinomethylene)]methaneaminium hexafluorophosphate), PyOxym-M, PyOxim (O-[(cyano(ethoxycarbonyl)-methylidene)amino]yloxytripyrrolidinophosphonium hexafluorophosphate), HONM (isonitrosome drumic acid), Ocyma-B, Oxyma-T, Amox, HMMU, Fmoc-Amox, and combinations thereof. In one example, the oxime coupling reagent is Oxymapure (2-cyano-2-(hydroxyimino)acetate).

[0109] In some embodiments, the amide coupling reagent is used in the reaction with respect to compound A5 in amounts of at least 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, or 3.5 equivalents. In some embodiments, the amide coupling reagent is used in the reaction with respect to compound A5 or formula 2 in amounts of less than 5, 4.5, 4, 3.5, 3, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2, 1.9, 1.8, 1.6, or 1.5 equivalents. With respect to compound A5 or formula 2, the equivalent amount of the amide coupling reagent used in the reaction may be provided within the range of any two of these upper and / or lower limits, for example, between about 1 to 3, 1.2 to 2, or 1.3 to 1.7. In one embodiment, the amide coupling reagent is a carbodiimide coupling reagent (e.g., DIC), and according to any embodiment described herein, the method should be understood to further include optionally one or more additives (e.g., HOPO and / or DIPEA).

[0110] The additive can be used with the amide coupling reagent. The additive may be any reagent that promotes / catalyzes the amide coupling reaction. For example, the additive is an N-oxide reagent, such as 2-hydroxypyridine-N-oxide (HOPO). The N-oxide reagent is N + -O - It should be understood that the bond is a pyridine N-oxide, which may be optionally substituted, such as HOPO. For example, the reagent may consist of a carbodiimide coupling reagent and any additives, or of a carbodiimide coupling reagent and any additives.

[0111] In some embodiments, an additive (e.g., HOPO) is used in the reaction in amounts of at least 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, or 3.5 equivalents with respect to compound A5. In some embodiments, the additive is used in the reaction in amounts of 5, 4.5, 4, 3.5, 3, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2, 1.9, 1.8, 1.6, or less than 1.5 equivalents with respect to compound A5. With respect to compound A5, the equivalent amount of the additive used in the reaction may be provided within the range of any two of these upper and / or lower limits, for example, between about 1 to 4, 1.1 to 3, or 1.2 to 2.

[0112] In some embodiments, the amount of base present is less than about 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, or 0.1 equivalents relative to the molar amount of compound A5. In some embodiments, the base is present in amounts greater than about 0.1, 0.3, 0.5, 0.7, 1, 1.5, 2, 2.5, 3, or 3.5 equivalents relative to the molar amount of compound A5. In some embodiments, the range of base presence is provided by any two of the above upper and / or lower limits for the additive, for example, 1 to 7, 2 to 6, or 2.5 to 4.5.

[0113] In another example, the reagent may consist of a carbodiimide coupling reagent and one or more additives, or a carbodiimide coupling reagent and one or more additives. In one example, the additive is an N-oxide reagent, e.g., 2-hydroxypyridine-N-oxide (HOPO). In another example, the additive is a base such as an amine (e.g., DIPEA). In yet another example, the reagent may consist of a carbodiimide coupling reagent (e.g., diisopropylcarbodiimide), an N-oxide additive (e.g., 2-hydroxypyridine-N-oxide), and a base additive (e.g., DIPEA).

[0114] In some embodiments, the coupling reagent is selected from the group consisting of at least one oxime coupling reagent and at least one carbodiimide coupling reagent, which may be provided according to any embodiment or example described herein. In one example, the coupling reagent is selected from the group consisting of oximapure (2-cyano-2-(hydroxyimino)acetate), EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), and 2-hydroxypyridine-N-oxide (HOPO). It should be understood that, according to any example described herein, one or more optional additives may be used.

[0115] Surprisingly, it has been found that amide coupling reactions can be carried out using at least one carbodiimide coupling reagent without the apparent formation of undesirable by-products (e.g., tetramethylurea, TMU). In some embodiments, the method involves using a specific combination of at least one carbodiimide coupling reagent, optionally at least one additive (e.g., an N-oxide, e.g., HOPO), and optionally at least one base (e.g., DIPEA), where the presence of undesirable by-products (e.g., tetramethylurea, TMU) is significantly reduced or avoided. In some embodiments, the method involves using DIC, optionally together with HOPO and / or DIPEA.

[0116] Those skilled in the art will understand that several suitable solvents can be used in the reaction. One or more of the solvents of compound A3, compound A4, compound A5, compound A8, or compound A9 can be used in the reaction to produce the compound of formula 1. In one example, the solvent is selected from the group consisting of water, alcohol, ester, ether, nitrile, or a combination thereof. The solvent may be an aqueous solvent. In one example, the solvent includes ethers such as cyclopentyl methyl ether (CPME) and 2-methyltrihydrofuran (2-MeTHF). In another example, the solvent includes an alcohol, such as isopropyl alcohol (IPA). In yet another example, the solvent includes a nitrile such as acetonitrile. In yet another example, the solvent includes acetonitrile. The solvent can be present in the reaction in any suitable amount to bring the reaction to fruition. In one example, the solvent in an aqueous solvent includes water and one or more organic solvents (e.g., nitrile solvents such as acetonitrile) according to any example described herein.

[0117] In some embodiments, the reaction involves an organic solvent that is either polar protic or aprotic. Examples of polar aprotic solvents include, but are not limited to, acetonitrile (ACN), dimethylformamide (DMF), dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate (Â), dimethyl sulfoxide (DMSO), acetone, hexamethylphosphate triamide (HMPT), dimethyl ketone, and methyl ethyl ketone. In one example, the organic solvent is a polar aprotic solvent, i.e., acetonitrile (ACN). The organic solvent is Me-THF.

[0118] In some embodiments, the reaction is carried out in an aqueous solvent such as water and a water-miscible solvent such as acetonitrile. Suitable examples of water-miscible solvents include alcohols, ethers, and nitriles. In one example, the aqueous solvent is a mixture of water and acetonitrile in a ratio of about 1:3 to about 3:1 or about 1:1.

[0119] In some embodiments, after the reaction is substantially complete, another solvent, such as an alcohol (e.g., ethanol), is added to the reaction mixture to promote the precipitation of the compound of Formula 1.

[0120] In some examples, the reaction mixture containing the additive selected from compound A5EA is stirred for about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, or about 6 hours before adding compound A9. In some embodiments, the reaction mixture is heated to a temperature between about 30°C and 90°C, 40°C and 80°C, or 50°C and 70°C. Examples of solvents include aqueous solvents such as water and acetonitrile (e.g., about 1:1).

[0121] In some embodiments, compound A9 of formula 3 is a secondary amine salt according to any of the examples described herein. For example, compound A9 of formula 3 is a secondary amine sulfonate such as p-toluenesulfonic acid (p-TSA) salt.

[0122] In some embodiments, a method for producing a compound of formula 1a is provided. [ka]

[0123] This manufacturing method involves using the carboxylic acid compound of formula 2a or a salt thereof, [ka]

[0124] This involves reacting a sulfonate (e.g., p-TSA) compound of formula 3a with a carbodiimide coupling reagent and optionally one or more additives. [ka] (In the formula, R is selected from alkyl, aryl, and alkylaryl, which may be optionally substituted.)

[0125] In some embodiments, the carboxylic acid compound of formula 2 is produced by saponifying the ester compound of formula 7 with a base. [ka] (In the formula, R 5は It is a hydrogen or amine protecting group, R 6 (This is an ester protecting group.)

[0126] R 6 It should be understood that the compound of formula 7 can be cleaved by base-catalyzed hydrolysis. In some embodiments, the base is selected from the group consisting of sodium hydroxide (NaOH), lithium hydroxide (LiOH), and potassium hydroxide (KOH). In one example, the base is lithium hydroxide (LiOH). Alternatively, R 6 It should be understood that the compound can be cleaved from the compound of formula 7 by acid-catalyzed hydrolysis. In some embodiments, before producing the carboxylic acid compound of formula 2, R in the compound of formula 7 is used. 5 Remove the amine protecting group.

[0127] Scale up The method described herein enables an expandable synthetic route and production of the compound of Formula 1. Compared to the method described in international patent application WO2011135276, the method described herein provides an increased total yield of compound 1, expandable reaction conditions, and avoids the generation of potentially toxic byproducts.

[0128] In some embodiments, this method is carried out on a small scale (e.g., from 20 mg to 1 g) suitable for research and development purposes. However, in some other embodiments, this method is carried out on a large scale (e.g., from 1 gram to over 50 grams), which is suitable for manufacturing purposes. Synthesis or one or more of its steps can be carried out as a batch method.

[0129] In some embodiments, the method for producing the compound of formula 4 is carried out using a starting material amount of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg of the compound of formula 5 or formula 6. That is, the method for producing the compound of formula 4 is carried out on a scale of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg. In one example, the method for producing compound A8 is carried out using a starting material amount of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg of compound A7 or compound A6. That is, the method for producing compound A8 is carried out on a scale of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg.

[0130] In some embodiments, this method provides conversion rates of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80% from the compound of formula 5 to the compound of formula 4, as measured by HPLC. It should be understood that the conversion rate of the reaction can be measured at any point in the reaction by any suitable technique such as TLC or HPLC. Typically, HPLC is performed on aliquots of the reaction mixture to identify the peaks of the relevant components and integrate them together. In some embodiments, the Grignard reaction described herein provides conversion rates of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80% from the compound of formula 5 to the compound of formula 4, as measured by HPLC.

[0131] As used herein, the term “yield” means, as understood by those skilled in the art, the amount of crude or purified compound obtained from a reaction, measured as a percentage of the theoretical yield of the compound in the reaction.

[0132] In some embodiments, this method provides a yield of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of the compound of formula 4, as measured from the starting materials of the compounds of formulas 5 and 6. That is, in some embodiments, the Grignard reaction described herein provides a yield of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of the compound of formula 4. In some embodiments, the Grignard reaction provides a yield of about 20% to 80%, about 30% to 70%, or about 50% to 70% of the compound of formula 4. In one example, the Grignard reaction provides a yield of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of compound A8. In some embodiments, the Grignard reaction described herein provides yields of compound A8 of about 20% to 80%, about 30% to 70%, or about 50% to 70%.

[0133] In some embodiments, the methods described herein provide a compound of formula 4 in high purity. As will be understood by those skilled in the art, purity is a measure independent of yield; that is, a compound may be of high purity despite a low yield. As used herein, the term “high purity” means that at least 80% of the final material obtained, which can be measured, for example, by HPLC, is the desired compound (e.g., formula 4). The purity of a compound can be measured based on the crude reaction mixture, the product separated from the reaction mixture (i.e., post-reaction treatment), or the purified product (i.e., after chromatography, recrystallization, etc.).

[0134] In some embodiments, the Grignard reaction described herein provides the compound of formula 4 with a purity of at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, or 95%. In one example, the Grignard reaction described herein provides the compound of formula 4 with a purity of at least 30%, 40%, or 50% of the product in the crude reaction mixture. In one example, the Grignard reaction described herein provides the compound of formula 4 with a purity of at least 50% of the product separated from the reaction mixture (i.e., after post-treatment). In one example, the Grignard reaction described herein provides the compound of formula 4 with a purity of at least 95% after purification. In one example, the Grignard reaction described herein provides the compound of formula 4 with a purity of at least 95% after recrystallization. In one example, the Grignard reaction described herein provides the compound of formula 4 with a purity of at least 95% after column chromatography.

[0135] In some embodiments, a method for producing the azabicyclo compound of formula 4 is provided. [ka]

[0136] This manufacturing method involves a Grignard reaction between the nortropinone compound of formula 5 and the halogenated compound of formula 6. [ka] (In the formula, R 1 The compound is selected from carbocyclyl or heterocyclyl, and each of the carbocyclyl and heterocyclyl compounds is either unsubstituted or contains a halogen, -OH, or -C. 1~6 Alkyl, -OC 1~6 Alkyl, -C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO2R 3 A monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of R 3 , and R4 These are, independently, hydrogen and -C> 1~6 Selected from the group consisting of alkyl, R 2 (where is an amine protecting group, X is a halogen, and the yield of the compound of formula 4 is at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%.)

[0137] In some embodiments, the method for producing the compound of formula 1 is carried out using a starting material amount of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg of the compound of formula 2 or formula 3. That is, the method for producing the compound of formula 1 is carried out on a scale of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg. In one example, the method for producing compound 1 is carried out using a starting material amount of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg of compound A5 or compound A9. That is, the method for producing compound 1 is carried out on a scale of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, or at least 10 kg.

[0138] In some embodiments, this method provides a conversion rate from the compound of formula 2 to the compound of formula 1 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80%, as measured by HPLC. In some embodiments, this method provides a conversion rate from the compound of formula 3 to the compound of formula 1 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80%, as measured by HPLC. In some embodiments, the amide coupling reaction described herein provides a conversion rate from the compound of formula 2 to the compound of formula 1 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80%, as measured by HPLC. In some embodiments, the amide coupling reaction described herein provides a conversion rate from the compound of formula 3 to the compound of formula 1 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80%, as measured by HPLC.

[0139] In some embodiments, this method provides a yield of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of the compound of formula 1, measured from the starting materials of the compound of formula 2 and the compound of formula 3. That is, in some embodiments, the amide coupling reaction described herein provides a yield of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of the compound of formula 1. In some embodiments, the amide coupling reaction described herein provides a yield of the compound of formula 1 between about 20% and 80%, about 30% and 70%, or about 50% and 70%. For example, the amide coupling reaction described herein provides a yield of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of compound 1. In some embodiments, the amide coupling reactions described herein provide compound yields between about 20% and 80%, about 30% and 70%, or about 50% and 70%.

[0140] In some embodiments, the methods described herein provide a compound of formula 1 in high purity. In some embodiments, the amide coupling reaction described herein provides a compound of formula 1 with a purity of at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In one example, the amide coupling reaction described herein provides a compound of formula 1 with a product purity of at least 80% in the crude reaction mixture. In one example, the amide coupling reaction described herein provides a compound of formula 1 with a purity of at least 80% of the product separated from the reaction mixture (i.e., after post-treatment). In one example, the amide coupling reaction described herein provides a compound of formula 1 with a purity of at least 95% after purification. In one example, the amide coupling reaction described herein provides a compound of formula 1 with a purity of at least 95% after recrystallization. In one example, the amide coupling reaction described herein provides a compound of formula 1 with a purity of at least 95% after column chromatography.

[0141] In some embodiments, a method for producing a heterocyclic methanone compound of formula 1 is provided. [ka]

[0142] This manufacturing method involves reacting a carboxylic acid compound of formula 2 or a salt thereof with an amine bicyclic compound of formula 3 or a salt thereof in the presence of at least one coupling reagent. [ka] (In the formula, R 1 The compound is selected from carbocyclyl or heterocyclyl, and each of the carbocyclyl and heterocyclyl compounds is either unsubstituted or contains a halogen, -OH, or -C. 1~6 Alkyl, -OC 1~6 Alkyl, C 1~6 Haloalkyl, -OC 1~6 Haloalkyl, -CN, -NR 3 R4 、 -COR 3 、 -CO2R 3 A monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of, R 3 , and R 4 are each independently hydrogen and C 1~6 alkyl, R 5 is hydrogen or an amine protecting group, and the yield of the compound of formula 1 is at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%).

[0143] compound In some embodiments, compounds of formula 1 produced by any of the methods described herein are provided.

Chemical formula

[0144] In some embodiments, compounds of formula 1a produced by any of the methods described herein are provided.

Chemical formula

[0145] In some embodiments, compounds of formula 4 produced by any of the methods described herein are provided.

Chemical formula

[0146] In some embodiments, compounds of formula 4a produced by any of the methods described herein are provided.

Chemical formula

[0147] In some embodiments or examples, one or more of the intermediate compounds described herein may be provided at any step of the method.

[0148] composition The compound of formula 1 or a salt thereof can be administered alone in some embodiments, but more typically can be administered as part of a pharmaceutical composition or formulation. Accordingly, the present disclosure also provides a pharmaceutical composition comprising a compound of formula 1 or a salt thereof and a pharmaceutically acceptable excipient. The pharmaceutical compositions of the present invention include one or more pharmaceutically acceptable diluents, carriers, or excipients (collectively referred to herein as "excipient" substances).

[0149] The present disclosure also provides pharmaceutical formulations or compositions for veterinary and human medical use comprising a compound of formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable carriers, and optional other therapeutic components, stabilizers, etc. The carrier must be pharmaceutically acceptable, i.e., compatible with the other ingredients of the formulation and not unduly harmful to its recipient.

[0150] Examples of pharmaceutical formulations may include, for example, formulations suitable for oral administration, parenteral administration (including subcutaneous, intradermal, intramuscular, intravenous and intra-articular), inhalation administration (including particulate dusts or mists that can be generated by various metered amounts of pressurized aerosols), nebulizers or insufflators, rectal, intraperitoneal and topical administration (including skin, oral, sublingual and intraocular), although this may depend on the condition and disorder of the subject being treated.

[0151] Pharmaceutical formulations can be conveniently provided in unit dosage forms and can be manufactured by any method known in the pharmaceutical field. Any method involves combining a compound of formula (I) or a salt thereof with excipients constituting one or more essential components. Generally, formulations are manufactured by homogeneously and tightly associating the active ingredient with a liquid carrier, a fine powder solid carrier, or both, and then, if necessary, shaping the product into the desired formulation.

[0152] In some embodiments, this composition is formulated for oral delivery. For example, pharmaceutical formulations of the present invention suitable for oral administration may be provided as powders or granules, as solutions or suspensions in aqueous or non-aqueous liquids, for example, as elixirs, tinctures, suspensions or syrups, or as individual units such as capsules, cachets, pills or tablets containing a predetermined amount of the active ingredient as an oil-in-water or water-in-oil liquid emulsion. The compounds of Formula 1 may also be provided as pills, tablets or pastes.

[0153] Tablets can be manufactured, for example, by compression or molding, and may use one or more auxiliary components. Compressed tablets can be manufactured by compressing an active ingredient, such as a powder or particles mixed with an optionally binder, lubricant, inert diluent, surfactant, or dispersant, in a free-flowing form in a suitable machine. Molded tablets can be manufactured by molding a mixture of powder compounds moistened with an inert liquid diluent in a suitable machine. Tablets may optionally be coated or etched and may be formulated to provide sustained-release or controlled-release of the compound of Formula 1. For example, the compound of Formula 1 may be suitable for administration in immediate-release or sustained-release form. Immediate-release or sustained-release can be achieved by using a suitable pharmaceutical composition containing the compound of Formula 1, or, especially in the case of sustained-release, by using a device such as a subcutaneous implant or infiltration pump. The compound of Formula 1 can also be administered via liposomes.

[0154] Exemplary compositions for oral administration include, for example, suspensions containing microcrystalline cellulose for bulking, alginic acid or sodium alginate as a suspending agent, methylcellulose as a thickener, and sweeteners or flavorings as known in the art; for example, immediate-release tablets containing microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate, calcium sulfate, sorbitol, glucose and / or lactose, and / or other excipients, binders, fillers, disintegrants, diluents, and lubricants as known in the art. Suitable binders include natural sugars such as starch, gelatin, glucose or β-lactose, corn sweeteners, natural and synthetic gums such as acacia, furanoco gum or sodium alginate, carboxymethylcellulose, polyethylene glycol, wax, etc. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, etc. Compounds of Formula 1 can also be delivered orally by sublingual and / or buccal administration. Exemplary forms may be molded tablets, compressed tablets, or lyophilized tablets. Exemplary compositions include compositions containing the compound of Formula 1 with a rapidly soluble diluent such as mannitol, lactose, sucrose, and / or cyclodextrin. These formulations also include high molecular weight excipients such as cellulose (avicel) and polyethylene glycol (PEGs). Such formulations may also contain excipients to aid mucosal adhesion, such as hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), sodium carboxymethylcellulose (SCMC), maleic anhydride copolymer, and release control agents such as polyacrylic acid copolymer. Lubricants, flow enhancers, fragrances, colorants, and stabilizers may also be added to facilitate manufacture and use. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, and sodium chloride. For oral administration in liquid form, the oral pharmaceutical component may be combined with any orally administered, non-toxic, and pharmaceutically acceptable inert carrier, such as ethanol, glycerin, or water.

[0155] In some embodiments, this composition is formulated for extra-gastrointestinal delivery. Extra-gastrointestinal formulations include aqueous and non-aqueous sterile injection solutions that may contain antioxidants, buffers, bacteriostatic agents, and solutes isotonic with the blood of the intended subject, and aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickeners. The formulations may be filled into unit-dose or multi-dose containers such as sealed ampoules and vials, and may be stored in a lyophilized state requiring only the addition of a sterile liquid carrier, such as saline or water for injection, immediately before use. Immediate injection solutions and suspensions can be prepared from the sterile powders, granules, and tablets of the types described above. Exemplary compositions for extra-gastrointestinal administration include, for example, mannitol, 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution, and other suitable non-toxic and extra-gastrointestinal acceptable diluents or solvents, or other suitable dispersants or wetting / suspending agents containing synthesized monoglycerin or diglycerin esters and fatty acids including oleic acid or cremahole.

[0156] For example, in one embodiment, the formulation may be a sterile lyophilized composition suitable for redissolution in an aqueous carrier before injection. In one embodiment, a formulation suitable for extra-gastrointestinal administration may conveniently include a sterile aqueous formulation of the compound of Formula 1, which can be formulated for the isopermeability of the receptor to the blood.

[0157] The compounds of Formula 1 of this disclosure can be incorporated into compositions, for example, that are suitable for inhalation into the lungs by aerosol or extra-gastrointestinal administration (including intraperitoneal, intravenous, subcutaneous, or intramuscular injection). The compositions can be conveniently provided in unit dosage forms and can be manufactured by any method known in the pharmaceutical field. Any method involves the step of attaching the compounds of Formula 1 to a carrier constituting one or more auxiliary components. Generally, the compositions are manufactured by combining the compounds of Formula 1 with a liquid vehicle to form a solution or suspension, or by combining the compounds of Formula 1 with a formulation component suitable for forming a solid (optionally a particulate product) and molding it into a desired delivery form as needed. When the solid dosage forms of this disclosure are particulate, they generally contain particles having a size in the range of about 1 nm to about 500 μm. Generally, for solid dosage forms for intravenous administration, the particle diameter is generally between about 1 nm and about 10 μm. The composition may contain the compound of Formula 1 of this disclosure, which is a nanoparticle having a particle size of less than 1000 nm, for example, 5 to 1000 nm, particularly 5 to 500 nm, more specifically 5 to 400 nm, for example 5 to 50 nm, particularly 5 to 20 nm. In one example, the composition contains the compound of Formula 1 having an average size between 5 and 20 nm. In some embodiments, the compound of Formula 1 is highly dispersed in the composition, and the PDI is between 1.01 and 1.8, particularly between 1.01 and 1.5, and even more particularly between 1.01 and 1.2. In one example, the compound of Formula 1 is monodisperse in the composition.

[0158] Furthermore, in addition to the components mentioned above, considering the type of formulation, it should be understood that other formulations conventionally used in this field may be included. For example, formulations suitable for oral administration may include flavoring agents.

[0159] The compositions of this disclosure may further include polymer excipients / additives or carriers such as polyvinylpyrrolidone, derivatized cellulose such as hydroxymethylcellulose, hydroxyethylcellulose and hydroxypropylmethylcellulose, Ficol (high molecular weight sugar), hydroxyethyl starch (HES), dextran esters (e.g., cyclodextrins such as 2-hydroxypropyl-β-cyclodextrin and sulfobutyl ether-β-cyclodextrin), polyethylene glycol and pectin. The compositions may also include diluents, buffers, citrates, trehalose, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g., benzalkonium chloride), sweeteners, antistatic agents, sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamine, fatty acids and fatty esters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA, zinc, and other suitable cations). Other pharmaceutical excipients and / or additives applicable to compositions based on this disclosure are described in "Remington: The Science & Practice of Pharmacy," 19th sup.th ed., Williams & Williams, (1995), and "Physician's Desk Reference," 52nd sup.nd ed., Medical Economics, Montvale, NJ (1998), and "Handbook of Pharmaceutical Excipients," 3rd edition, AH Kibbe, Pharmaceutical Press, 2000. In some embodiments, compounds of formula 1a are provided having a purity of at least about 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or 99.9 (based on the weight percent of the total composition containing the compound of formula 1a). [ka]

[0160] For the compounds of formula 1a, high purity may be achieved if impurities are present, in amounts (weight %) less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.05, 0.001, 0.005, or 0.0001. The compound may be substantially free of impurities. The impurities may be selected from one or more by-products or reagents used in the method herein, such as TMU, THP, and / or iodopyrimidine. In one example, the impurity (if present) is TMU. The high-purity compound can be obtained from the crude reaction composition of the amide coupling reaction step in the preparation of the compound of formula 1a. The compound may also be purified from the crude reaction composition (e.g., by washing and / or solvent extract). As described herein, the high-purity compound of formula 1a may be provided in a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients. These pharmaceutical compositions are provided according to any of their embodiments or examples.

[0161] In some embodiments, compositions are provided comprising a compound of formula 1a and one or more excipients according to any embodiment or example described herein. [ka]

[0162] The amounts (weight % based on the total weight of the composition) of these impurities (if present) are less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may substantially contain no impurities. The impurities may be selected from any one or more by-products or reagents used in the methods described herein, such as TMU, THP, DIPU, and / or iodopyrimidine. In one example, the impurity (if present) is TMU. This composition may be the crude reaction composition of the amide coupling reaction step when producing the compound of formula 1a. The composition may be a purified product of the crude reaction composition (e.g., a wash and / or solvent extract). The composition may be a pharmaceutical composition containing one or more pharmaceutically acceptable excipients according to any embodiment or example described herein.

[0163] The present disclosure will now be described with reference to the following examples, which illustrate certain specific aspects of the present disclosure. However, it should be understood that the particularity of the following description of the present disclosure does not replace the generality of the foregoing description of the present disclosure.

Examples

[0164] Summary: Materials and Methods Unless otherwise specified, all solvents and reagents were obtained from commercial sources.

[0165]

Table 1

Chemical Formula

[0166] Example 2: Synthesis of Compound A4 [ka] A solution of 2-methyltetrahydrofuran containing A3 was placed in a reaction vessel. The solution was heated to 50°C, and 4 equivalents of hydrochloric acid were gradually added. After the addition, the suspension was cooled to 0°C and stirred for 30 minutes while cooling. The suspension was then filtered, and the solid was dried under reduced pressure. The light brown solid was suspended in 1 volume equivalent of 2-methyltetrahydrofuran, and potassium carbonate solution was added dropwise until the pH was 10-12. The two phases were separated. The solvent was removed from the organic layer under reduced pressure. The brown solid was suspended in 5 volume equivalents of isopropyl acetate, heated under reflux, and filtered to obtain a clear solution. The clear solution was gradually cooled to 0°C and stirred overnight. The light brown suspension was filtered, and the solid was dried to obtain A4. Cleavage of the THP protecting group Screening was conducted to determine which acid, in what quantity, and at what temperature is preferable for cleaving the tetrahydropyran (THP) group. The results showed that the THP group was successfully cleaved by prolonging an excess of hydrochloric acid in water or isopropyl alcohol at approximately 55°C for about 24 hours. Good cleavage of the THP group was also achieved with H2SO4 and ethanol at approximately 80°C for about 48 hours, although ester saponification was observed. Ultimately, hydrochloric acid was preferred as the THP group cleavage agent. Furthermore, an organic hydrochloric acid solution was used to ensure that the A4 salt was not included in the solution, was cleanly filtered out, and the balance was maintained. recrystallization Small-scale test crystallization was performed in isopropyl alcohol and isopropyl acetate under the following conditions. 48 mg of A4 was added to two vials and diluted with 0.73 ml (15 volume equivalents) of isopropyl alcohol and isopropyl acetate, respectively. Both were heated and refluxed (both became clear brown solutions) and gradually cooled to room temperature. Both were filtered at room temperature and analyzed by HPLC to determine the yield. [Table 2] Since the yield was high and no new impurities were generated, we decided to recrystallize the product in isopropyl acetate. The remaining crude A4 was diluted with 10 volume equivalents of isopropyl acetate and heated under reflux. The substrate was dissolved at approximately 10°C before reflux. After gradually cooling the solution to 20°C, the solid was filtered and dried under reduced pressure at 50°C. The yield for relatively large-scale recrystallization was 77%. Recrystallization was further optimized by using already purified materials. A4 was dissolved in 5 volume equivalents of isopropyl acetate and refluxed. The mixture was then filtered to make it clear and cooled. A solid with a purity of over 98% was obtained.

[0167] Example 3: Synthesis of Compound A5 [ka] Saponification with lithium hydroxide monohydrate Solution A4 in 2-methyltrihydrofuran (2-Me-THF) was added to a reaction vessel in water (5 volume equivalents) along with a lithium hydroxide monohydrate solution (3 equivalents). The mixture was stirred overnight at 35°C. Complete conversion to A5 was observed. No workup or purification was performed. Saponification with sodium hydroxide solution Solubility tests showed that A5 is soluble in water at pH 4. A4 was saponified under aqueous conditions. A4 was suspended in an aqueous sodium hydroxide solution consisting of water (7.3 volume equivalents) and 1.3 equivalents of sodium hydroxide dissolved in 3 volume equivalents of water. The mixture was then heated to 65°C. Complete inversion was observed after 1 hour. The mixture was cooled to 45°C, and HCl was added dropwise to adjust the pH to 5. The resulting suspension was cooled to 10°C and filtered. The solid was dried and analyzed by HPLC (97.86%). Yield: 86.91%

[0168] Example 4: Synthesis of Compound A8 [ka] Halogen-metal exchange reaction We screened halogen-metal exchange reagents, including the following Grignard reagents. i-PrMg.LiCl ("Turbo Grignard") i-PrMgBr, and sec-BuMgCl.LiCl. Based on screening, all of the above Grignard reagents showed that compound A6 was completely consumed (i.e., no residual starting material was detected) by HPLC-UV after 0.5 to 1 hour at approximately 0°C, preferably in amounts of approximately 1.05 to 1.11 equivalents of Grignard reagent. Coupling reaction A screening was conducted for studies on the binding of p-tolylmagnesium bromide with Boc-nortropinone. Next, the reactions were screened at room temperature using the following seven different additives (reagents and equivalents). Additives: CeCl3, LaCl3, 2LiCl, MnCl2 Equivalents: 1.5, 2.0 LaCl3 exhibits a conversion independent of the equivalent used. summary The halogen-metal exchange reaction of compound A6 reacted well with different Grignard reagents. Coupling with Boc-nortropinone using LaCl3.2LiCl3 yielded a good conversion rate to compound A8. The next step is to combine these two steps to study the coupling of Boc-nortropinone with compound A6 using different Grignard reagent / additive combinations. Screening of Grignard reagent / additive combinations The following table outlines the screening criteria. [Table 3] TIFF2023548368000053.tif171164TIFF2023548368000054.tif154161

[0169] *Comparative Example Overall results Based on the experiments, it was found that the combination of i-PrMgBr and LaCl3 is preferable for the synthesis of compound A8. Dioxane and Me-THF also showed incorrect reaction results. Screening of addition order, addition time, and stirring time. To evaluate the effect of the reagent addition order on the reaction, further screening was performed as follows. The order of addition of different reagents / reagent mixtures at room temperature (addition time 1 hour). The reagent added last to the mixture is shown below. Add nortropinone (and all other reagents already present). Add compound A6 + i-PrMgBr + LaCl3. Add nortropinone + LaCl3. Add compound A6 + i-PrMgBr. Three additional addition sequences at RT and -78°C: Compound A6 -> LaCl3 -> i-PrMgBr -> nortropinone; i-PrMgBr -> LaCl3 -> compound A6>-nortropinone, and One-pot reaction (room temperature) Reaction time of compound A6 + i-PrMgBr (with and without LaCl3): 30 minutes, and 16 hours In a 1-hour addition screening, no significant difference was observed, and the conversion rate of A8 ranged from 54% to 64%. In the first two addition sequences tested, the reaction was exothermic, with conversion rates of only 30-35%, and IPC HPLC purities at room temperature were very low, at 11.6% and 24.0%. No reaction occurred at -78°C. The reaction only occurred when heated to RT, with conversion rates of 61%-73%. While this conversion appears promising, its accumulation poses a high security risk and is therefore considered unsuitable for large-scale implementation. The one-pot reaction (with i-PrMgBr added as the final reagent) resulted in various by-products. The reaction time after adding the Grignard reagent i-PrMgBr to compound A6 was investigated. Reactions with a reaction time of 30 minutes before adding Boc-nortropinone showed a better conversion rate than reactions with a reaction time of 16 hours. LaCl3 also affected the conversion rate and purity. Reactions in which LaCl3 was present in the reaction mixture from the beginning occurred more readily than reactions in which LaCl3 was added simultaneously with or immediately before nortropinone. Therefore, LaCl3 should be added immediately before or simultaneously with nortropinone. Screening of equivalent weight and temperature First, a preliminary screening was performed to investigate the effects of different equivalents of LaCl3 (0.2 / 1.5 / 2.0 / 2.5) on RT. Using 1.5 equivalents of LaCl3 yielded the best results in terms of conversion rate and purity. In other cases, 2.0 equivalents of LaCl3 showed a slightly better conversion rate, but inferior purity. In the next step, four different parameters, each with three different settings, were screened to determine the best conditions, resulting in a total of nine reactions. Equivalent amounts of i-PrMgBr: 1.2 / 1.5 / 1.8; Equivalent amounts of LaCl3: 0.5 / 1.0 / 1.5; Halogen-metal exchange temperature: -20°C / 0°C / RT; and Temperature response: -20℃ / 0℃ / RT As a result, it was found that the following parameters represent the optimal conditions. i-PrMgBr: 1.5 eq.; LaCl3: 1.5 eq.; Heat exchange temperature: -20°C, Temperature response: 0℃ Verification reaction: Verification was performed using 2.0 g of BOC-nortropinone under optimized conditions. Compound A6 was added, diluted with 2-Me-THF, and cooled to -20°C. i-PrMgBr was added at -20 to -15°C to obtain a yellow suspension. After stirring for 30 minutes, the mixture was heated to 0°C. A THF solution of Boc-norfortropinone and LaCl3 was added dropwise at 0-5°C for 30 minutes. After 1.5 hours, IPC showed 35% Boc-norfortropinone / 65% compound A8 and an IPC HPLC purity of 51.2% (see Figure 1). The reaction was quenched with aqueous citrate (5%), extracted with 2-Me-THF, and the organic phase was washed with aqueous sodium chloride (5%). The organic phase was evaporated to dryness, and 4.1 g of crude product was obtained with an HPLC assay of 31.0% and an HPLC purity of 19.4 area% (the remainder being 9.7 area% nortropinone and 68.1% compound A6) (see Figure 2). Crystallization from heptane yielded 0.55 g of purified product (yield: 20.1%) with an HPLC purity of 99.3 area% (see Figure 3, HPLC chromatogram of the purified product). Screening of scale-up reactions In most previous tests, 2.0 equivalents of compound A6 were used to ensure the complete conversion of available (undeprotonated) Boc-nortropinone. Since compound A6 is an expensive starting material, we decided to test the reaction with a lower amount of compound A6 (1.5 equivalents). Furthermore, we investigated whether the excess or deficiency of i-PrMgBr (relative to compound A6) was suitable for scale-up reactions. Two experiments were performed on a 2.0 g scale. The reaction conditions were the same as above (1.0 equivalent of nortropinone / 1.5 equivalents of LaCl3 / -20°C to 0°C). The equivalents of i-PrMgBr (1.7 and 1.3 equivalents, respectively, instead of 2.0 equivalents) and compound A6 (2.0 equivalents to 1.5 equivalents) were different. In the initial experiment, an excess amount of i-PrMgBr (1.7 eq.) was used. IPC showed that after stirring overnight at 0°C, the ratio of compound A6 to nortropinone was 62.4%–37.6%, and the HPLC purity was 37.3 area% (after 2 hours, the purity was 43.3% => decomposed overnight due to side reactions with residual i-PrMgBr). After workup, 5.86 g of crude compound A8 (32.7% nortropinone and 3.2% compound A6) was obtained with an assay (by qNMR) of 20.9% and an HPLC purity of 60.7 area%. The calculated assay-corrected maximum yield was 45.4% (see Figure 4: Crude HPLC chromatography and Figure 5: Quantitative nuclear magnetic resonance). In the second experiment, nonwoven i-PrMgBr (1.3 eq.) was used. IPC showed that after stirring overnight at 0°C, the ratio of compound A6 to nortropinone was 60%–40%, and the HPLC purity was 44.9 area% (compound A6 was not integrated due to excess). 5.47 g of crude product of compound A8 (14.6% nortropinone and 52.1% compound A6) was obtained with an assay purity of 24.0% (by NMR) and an HPLC purity of 25.2 area%. The calculated assay-corrected maximum yield was 48.3% (see Figure 6: Crude HPLC chromatogram and Figure 7: Crude NMR). Based on these results, scale-up was performed using approximately 1.3 equivalents of i-PrMgBr to prevent degradation after "complete" conversion. Reducing the equivalent amount of compound A6 did not negatively affect the conversion rate, but it had a positive impact on the manufacturing cost (reduced the required amount of compound A6), so this measure was also implemented. Implementation of scale-up conditions Compound A6 was added, diluted with 2-Me-THF, and cooled to -20°C. i-PrMgBr was added at -20 to -15°C to obtain a yellow suspension. After stirring for 30 minutes, the mixture was heated to 0°C. A THF solution of Boc-nortropinone and LaCl3 was added dropwise at 0-5°C for no more than 30 minutes. After 2.5 hours, IPC showed 47% Boc-nortropinone / 53% compound A8 and an IPC HPLC purity of 42.9%. The reaction was quenched with aqueous citrate (5%), extracted with 2-Me-THF, and the organic phase was washed with aqueous sodium chloride (5%). The organic phase was divided into two parts of similar size. The organic phase was evaporated to dryness, yielding 24.5 g and 25.0 g of crude products, respectively, with NMR assay yields of 35.9% and 34.6% (assay-corrected yield: 43.2% / 42.6%) and HPLC purity of 24.6 area% (the remainder being 21.2 area% nortropinone and 52.3% A6). Purification of compound A8: Compound A8 was purified by chromatography using a heptane / alkyl gradient (yield: 33%, purity: 93.8 area%), and crystallized from heptane (total yield: 28%, purity: 97.2%). Overview of the Grignard Route Development More than 100 reactions were performed in total to develop an alternative Grignard route. Finally, reaction conditions were developed that show a reaction curve and yield very similar to the BuLi method in the literature, but without the need for cryogenic temperatures. For scale-up, a method that does not use chromatography (i.e., a method of scaling up compound A8 to the synthesis of compound A9) is preferred. To avoid the generation of new impurities during scale-up, iodopyrimidine was removed by extraction or derivatization. To avoid difficulties in purification, crude compound A8 was telescoped into compound A9, and purification was performed after this step.

[0170] Example 5: Synthesis of Compound A9 [ka] Scale-up telescope reaction Crude compound A8 was telescoped into a Boc cleavage reaction. Sulfonic acid was also used to deprotect Boc, producing a stable deprotected salt compound. Crude compound A8 (50 g) was dissolved in an aqueous solution of 4-toluenesulfonic acid (p-TSA or TsOH) monohydrate (0.5 M, 3.5 equivalents). This mixture was heated to 50°C and stirred for 1-2 hours. After IPC indicated that compound A8 in the supernatant was completely consumed, the turbid mixture was allowed to cool to room temperature. The resulting precipitate was filtered and rinsed with MeTHF. After vacuum drying at room temperature, the pTSA salt of compound A9 was obtained as a colorless to grayish-white solid (purity over 99% with a yield of 36.9%, see Figure 9). This salt was also identified to determine the 2:1 composition of pTSA:compound A9. NMR assay of this salt showed a purity of 99.6%.

[0171] Example 6: Synthesis of Compound 1 [ka] To a suspension of compound A5a (1.00 equivalent), compound A9 (EU1H2*2pTSA (1.10 equivalent), and HOPO (1.50 equivalent)) in acetonitrile / water (1:1 v / v, 31.0 v / w), DIPEA (3.5 equivalents) was added, and the resulting mixture was stirred for 5 minutes. The DIC (1.50 equivalent) mixture was heated to 60°C and stirred until EU1D2 was completely consumed (6-19 hours). The acetonitrile was distilled, and the mixture was allowed to cool to room temperature. It was acidified by slowly adding 2M HCl (1.0 equivalent) and aqueous NaHCO3. The layers were washed with iPrOAc (3 x 21.3 v / w). EtOH (7.5 The mixture was heated to 45°C with the addition of v / w (NaOH). NaOH (30%, 1.00 equivalent) was added dropwise until the pH reached 12. Seeds were used to purify the product before drying to remove the solvent. Evaporation under reduced pressure yielded compound 1 as a grayish-white solid with a purity of 99.7 area% (20.1 g, 82.4%) (see Figure 12). Oximapure and EDC were also used in the amide coupling reaction. 6.5 g of compound A5 was dissolved in 13 volume equivalents of acetonitrile. Oximapure was added, and the suspension was cooled to -10°C. EDC x HCl was added, and the mixture was stirred for 30 minutes. Then, DIPEA and compound A9 were added. The mixture was raised to room temperature. Over time, the mixture became a solution. After the reaction was complete, half of the reaction mixture was taken and tested with the proposed aqueous workup. Workup: The reaction mixture was added dropwise to three times the volume of water as acetonitrile to obtain a light suspension. Solid sodium carbonate was added until the pH was 9-12. Then, the solvent was removed under reduced pressure and replenished twice with 2 volume equivalents of water. The solid was suspended in water, and 60% H2SO4 was added until the pH was 0. Then, this solution was washed twice with Me-THF to remove the coupling reagent. Concentrated sodium hydroxide solution was added until the pH was 11. The mixture was heated to 50°C and saturated with Na2SO4. Subsequently, the mixture was extracted twice using a Me-THF / EtOH(3 / 1) mixture. The organic layer was then dried under reduced pressure to obtain an orange solid as the crude product. High-performance liquid chromatography: 97.71% area. Nuclear magnetic resonance: 41.47%. NMR analysis of the reaction mixture showed that 79% of the theoretical amount of compound 1 was present in the acetonitrile solution. Crude compound 1 was suspended in EtOH / H2O 1 / 1 1 / 16 volume equivalents and heated to 82°C. The mixture was then cooled to 0°C and filtered. The solid was then stirred with 2 volume equivalents of water at 0°C for 30 minutes and filtered again. This solid was dried at 50°C under reduced pressure to obtain 3.24 g of pure compound 1 as a gray solid. HPLC area %: 98.53%. qNMR: 97.67% (see Figure 14).

Claims

1. A process for the preparation of azabicyclo compounds of formula 4 comprising a Grignard reaction of nortropinone compounds of formula 5 with halogenated compounds of formula 6. 【Chemistry 1】 (In the formula, The R 1 is selected from carbocyclyl or heterocyclyl, each of which is independently unsubstituted or substituted with halogen, —OH, —C 1~6 Alkyl, —O—C 1~6 Alkyl, -C 1~6 Haloalkyl, —O—C 1~6 Haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO 2 R 3 is a monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of 3 and R 4 are each independently hydrogen or -C 1~6 is selected from the group consisting of alkyl, The R 2 is an amine protecting group, The X is a halogen.

2. The R 1 are each unsubstituted or substituted with halogen, OH, -C 1~6 Alkyl, —O—C 1~6 Alkyl, C 1~6 Haloalkyl, and —O—C 1~6 2. The method of claim 1, wherein the heteroaryl is a monocyclic or bicyclic heteroaryl substituted with one or more substituents selected from the group consisting of haloalkyl.

3. The R 1 The method of claim 1 or 2, wherein is a pyrimidine.

4. The R 2 The method of any one of claims 1 to 3, wherein is an amine protecting group selected from the group consisting of urethane, amide, benzyl, benzylidene, tosyl and trityl.

5. The R 2 The method according to any one of claims 1 to 4, wherein is t-butoxycarbonyl (BOC).

6. 6. The method of any one of claims 1 to 5, wherein the azabicyclo compound of formula 4 is a protected amine compound of formula 4a, comprising reacting a tropinone compound of formula 5a with a halogenated compound of formula 6a. 【Chemistry 2】 【change】

7. 7. A process for preparing a salt of an amine bicyclic compound of formula 3 comprising removing the amine protecting group from an azabicyclic compound of formula 4 prepared by the process of any one of claims 1 to 6 with a sulfonic acid to form the sulfonate salt thereof. 【Chemistry 3】

8. 8. The method of claim 7, wherein the salification comprises 4-toluenesulfonic acid (p-TSA) to produce a p-TSA salt of formula 3.

9. 1. A method for preparing a heterocyclic methanone compound of formula 1, comprising reacting a carboxylic acid compound of formula 2, or a salt thereof, with an amine bicyclic compound of formula 3, or a salt thereof, in the presence of at least one coupling reagent selected from an oxime coupling reagent and a carbodiimide coupling reagent. 【Chemistry 4】 【change】 (In the formula, R 1 is selected from carbocyclyl or heterocyclyl, each of which is unsubstituted or substituted with halogen, —OH, —C 1~6 Alkyl, —O—C 1~6 Alkyl, C 1~6 Haloalkyl, —O—C 1~6 Haloalkyl, -CN, -NR 3 R 4 , -COR 3 , -CO 2 R 3 is a monocyclic or bicyclic group substituted with one or more substituents selected from the group consisting of 3 , and R 4 are each independently hydrogen and C 1~6 is selected from the group consisting of alkyl, The R 5 is hydrogen or an amine protecting group.

10. 10. The method of claim 9, wherein the coupling reagent comprises an oxime coupling reagent selected from the group consisting of Oxymapure (2-cyano-2-(hydroxyimino)acetate), K-Oxyma (potassium 2-cyano-2-(hydroxyimino)acetate), COMU (1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethyl-aminomorph-olinomethylene)]methanaminium hexafluorophosphate), PyOxym-M, PyOxim (O-[(cyano(ethoxycarbonyl)-methylidene)amino]yloxytripyrrolidinophosphonium hexafluorophosphate), HONM (isonitrosomeldrum's acid), Ocyma-B, Oxyma-T, Amox, HMMU, and Fmoc-Amox.

11. 11. The method of claim 9 or 10, wherein the coupling reagent comprises a carbodiimide coupling reagent selected from the group consisting of DCC (dicyclohexylcarbodiimide), DIC (diisopropylcarbodiimide), EDAC.HCl (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide.HCl), and EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide).

12. The method according to any one of claims 9 to 11, wherein the coupling reagent is a carbodiimide coupling reagent selected from DIC (diisopropylcarbodiimide).

13. The method of claim 9, further comprising one or more additives selected from N-oxide reagents and bases.

14. The method of claim 13, wherein the N-oxide reagent is 2-hydroxypyridine-N-oxide (HOPO).

15. The method of claim 13, wherein the base is N,N-diisopropylethylamine (DIPEA).

16. The R 1 are each unsubstituted or substituted with halogen, OH, -C 1~6 Alkyl, —O—C 1~6 Alkyl, C 1~6 Haloalkyl, and —O—C 1~6 The method of any one of claims 9 to 15, wherein the heteroaryl is a monocyclic or bicyclic heteroaryl substituted with one or more substituents selected from the group consisting of haloalkyl.

17. The R 1 The method of any one of claims 9 to 16, wherein is a pyrimidine.

18. The R 5 The method of any one of claims 9 to 17, wherein is an amine protecting group THP.

19. The method of any one of claims 9 to 18, wherein the compound of formula 3 is a sulfonate salt.

20. 20. The method of any one of claims 9 to 19, wherein the heterocyclic methanone compound of formula 1 is a compound of formula 1a, comprising reacting a carboxylic acid compound of formula 2a, or a salt thereof, with a sulfonate salt of formula 3a in the presence of a carbodiimide coupling reagent. 【Chemistry 5】 【change】 wherein R is selected from alkyl, aryl, and alkylaryl, each of which may be optionally substituted.

21. The method according to any one of claims 9 to 20, wherein the carboxylic acid compound of formula 2 is prepared by saponifying an ester compound of formula 7 with a base. 【Chemistry 6】 (Wherein, R 5 is hydrogen or an amine protecting group, 6 is an ester protecting group.

22. A compound of formula 1 prepared by the method of any one of claims 9 to 21. 【Chemistry 7】